Diazoxide-Induced Hypertrichosis in a Neonate With Transient Hyperinsulinism
Clinical Medicine Insights: Case Reports, 2023 Diazoxide is one of the FDA-approved pharmacologic treatments for hyperinsulinemic hypoglycemia, however, its adverse effects in infants are not well described. We reported a 37-week-old boy with the diagnosis of hypoglycemia.
Seyyed Javad Boskabadi +3 more
doaj +2 more sources
Clinical and Hormonal Characteristics and Short-Term Outcomes of Diazoxide Use in Hypoglycemic Neonates: A Retrospective Cohort Study [PDF]
ChildrenBackground/Objectives: Diazoxide is used for persistent or recurrent hypoglycemia when the clinical and biochemical pattern is compatible with hyperinsulinism, but neonatal treatment populations are heterogeneous.
Sevil Bali, Burcu Cebeci
doaj +2 more sources
Diazoxide for Neonatal Hyperinsulinemic Hypoglycemia and Pulmonary Hypertension [PDF]
Children, 2022 Hypoglycemia in neonates is associated with long-term neurodevelopmental effects. Hyperinsulinemic hypoglycemia (HH) is the most common cause of persistent hypoglycemia in neonatal intensive care units.
Shoshana Newman-Lindsay +2 more
doaj +2 more sources
From standard to individualized diazoxide therapy in congenital hyperinsulinism: a narrative review [PDF]
Frontiers in PharmacologyPurposeCongenital hyperinsulinism (CHI) is the commonest cause of persistent hypoglycaemia in neonates and infants (blood glucose <3.0 mmol/L in first 2–3 days of life; <3.5 mmol/L after 3 days of life).
Teresa Wong +10 more
doaj +2 more sources
Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. [PDF]
, 2010 OBJECTIVE: The phenotype associated with heterozygous HNF4A gene mutations has recently been extended to include diazoxide responsive neonatal hypoglycemia in addition to maturity-onset diabetes of the young (MODY).
SE Flanagan (21320006) +12 more
core +11 more sources
Pulmonary hypertension occurring with diazoxide use in a preterm infant with hypoglycemia
Drug, Healthcare and Patient Safety, 2019 Ranjit I Kylat Division of Neonatal-Perinatal Medicine and Developmental Biology, Department of Pediatrics, The University of Arizona, College of Medicine, Tucson, AZ, USA Abstract: Pharmacologic modulation to open the KATP channels with diazoxide is ...
Kylat RI
doaj +2 more sources
Necrotizing enterocolitis following diazoxide therapy for persistent neonatal hypoglycemia [PDF]
Journal of Pediatric Surgery Case Reports, 2020 Recalcitrant neonatal hypoglycemia poses a treatment challenge for clinicians. When a patient's hypoglycemia does not respond to dextrose infusion, several medication options are available, including diazoxide(1,2).
Christina M. Theodorou, Shinjiro Hirose
doaj +2 more sources
Diazoxide promotes oligodendrocyte precursor cell proliferation and myelination. [PDF]
PLoS ONE, 2010 Several clinical conditions are associated with white matter injury, including periventricular white matter injury (PWMI), which is a form of brain injury sustained by preterm infants.
Birgit Fogal +4 more
doaj +2 more sources
Safety and feasibility of hyperkalemic cardioplegia with diazoxide in cardiac surgery: The Cardioplegia with Diazoxide in Cardiac Surgery TrialCentral MessagePerspective [PDF]
JTCVS OpenBackground: We have demonstrated cardioprotection by the adenosine triphosphate–sensitive potassium (KATP) channel opener diazoxide in multiple animal models in an effort to reduce myocardial stunning following cardiac surgery.
AlleaBelle Bradshaw, MD +7 more
doaj +2 more sources
A case of insulinoma effectively treated with low-dose diazoxide
Clinical Case Reports (discontinued), 2020 Diazoxide is a benzothiadiazine that can be effective in managing hypoglycemia in frail patients with surgical risk. We report here a case of insulinoma effectively treated with diazoxide, as our report will be helpful for similar cases.
Toshiro Seki +2 more
exaly +2 more sources